Id: | acc5046 |
Group: | 1sens |
Protein: | p70S6K |
Gene Symbol: | RPS6KB1 |
Protein Id: | P23443 |
Protein Name: | KS6B1_HUMAN |
PTM: | phosphorylation |
Site: | Thr389 |
Site Sequence: | SQFDSKFTRQTPVDSPDDSTL |
Disease Category: | Eye diseases |
Disease: | Neovascular Eye Disease |
Disease Subtype: | |
Disease Cellline: | HUVECs |
Disease Info: | |
Drug: | Curcumolide |
Drug Info: | Curcumolide is a compound with potential pharmacological activities. It may have certain effects on specific physiological processes and is an object of research in the field of pharmacology. |
Effect: | modulate |
Effect Info: | "Curcumolide can inhibit the phosphorylation of VEGFR2, thereby suppressing the phosphorylation of multiple downstream proteins and inhibiting the formation of retinal neovascularization. It may be a potential candidate drug for the treatment of proliferative diabetic retinopathy." |
Note: | |
Score: | 4.0 |
Pubmed(PMID): | 31450226 |
Sentence Index: | 31450226_10 |
Sentence: | Intravitreal injection of curcumolide reduced the formation of retinal neovascular tufts and VEGFR2 phosphorylation in the murine OIR model at concentrations administered without definite cellular and retinal toxicities. |
Sequence & Structure:
MRRRRRRDGFYPAPDFRDREAEDMAGVFDIDLDQPEDAGSEDELEEGGQLNESMDHGGVGPYELGMEHCEKFEISETSVNRGPEKIRPECFELLRVLGKGGYGKVFQVRKVTGANTGKIFAMKVLKKAMIVRNAKDTAHTKAERNILEEVKHPFIVDLIYAFQTGGKLYLILEYLSGGELFMQLEREGIFMEDTACFYLAEISMALGHLHQKGIIYRDLKPENIMLNHQGHVKLTDFGLCKESIHDGTVTHTFCGTIEYMAPEILMRSGHNRAVDWWSLGALMYDMLTGAPPFTGENRKKTIDKILKCKLNLPPYLTQEARDLLKKLLKRNAASRLGAGPGDAGEVQAHPFFRHINWEELLARKVEPPFKPLLQSEEDVSQFDSKFTRQTPVDSPDDSTLSESANQVFLGFTYVAPSVLESVKEKFSFEPKIRSPRRFIGSPRTPVSPVKFSPGDFWGRGASASTANPQTPVEYPMETSGIEQMDVTMSGEASAPLPIRQPNSGPYKKQAFPMISKRPEHLRMNL
Select PDB:
Target | Drug name | MOA | Phase | Status | Disease | Source |
---|---|---|---|---|---|---|
RPS6KB1 | TAS0612 | Ribosomal protein S6 kinase (P70S6K) inhibitor | 1 | Recruiting | neoplasm | ClinicalTrials |
RPS6KB1 | MSC-2363318A | Ribosomal protein S6 kinase (P70S6K) inhibitor | 1 | Completed | neoplasm | ClinicalTrials |
RPS6KB1 | LY-2780301 | Ribosomal protein S6 kinase (P70S6K) inhibitor | 1 | Completed | lymphoma | ClinicalTrials |
RPS6KB1 | XL-418 | Ribosomal protein S6 kinase (P70S6K) inhibitor | 1 | Suspended | neoplasm | ClinicalTrials |
RPS6KB1 | LY-2584702 | Ribosomal protein S6 kinase 1 inhibitor | 1 | Terminated | renal cell carcinoma | ClinicalTrials |
RPS6KB1 | LY-2584702 | Ribosomal protein S6 kinase 1 inhibitor | 1 | Terminated | non-small cell lung carcinoma | ClinicalTrials |
RPS6KB1 | LY-2584702 | Ribosomal protein S6 kinase 1 inhibitor | 1 | Terminated | metastasis | ClinicalTrials |
RPS6KB1 | LY-2780301 | Ribosomal protein S6 kinase (P70S6K) inhibitor | 1 | Completed | metastasis | ClinicalTrials |
RPS6KB1 | LY-2584702 | Ribosomal protein S6 kinase 1 inhibitor | 1 | Terminated | neuroendocrine neoplasm | ClinicalTrials |
RPS6KB1 | LY-2584702 | Ribosomal protein S6 kinase 1 inhibitor | 1 | Completed | cancer | ClinicalTrials |
RPS6KB1 | LY-2584702 | Ribosomal protein S6 kinase 1 inhibitor | 1 | Terminated | cancer | ClinicalTrials |
RPS6KB1 | XL-418 | Ribosomal protein S6 kinase (P70S6K) inhibitor | 1 | Suspended | cancer | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACRPS6KB1-Thr389 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | |
HGSC | |
ccRCC | 0.707 |
GBM | -0.707 |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
T | 389 | P | Liver cancer | Phosphorylation | 23537100 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.